tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-1-42-46tumors-326Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSСистемы критериев оценки ответа солидных опухолей при лечении иммуноонкологическими препаратамиSystems of response evaluation criteria in solid tumors in immunooncology treatmentЮДИНД. И.YUDIND. I.

к. м.н., с. н.с.

MD, PhD, senior staff scientist

yudinden@mail.ruЛАКТИОНОВК. П.LAKTIONOVK. P.

профессор, в. н.с

professor, leading researcher

Laktionov.K@mail.ruСАРАНЦЕВАК. А.SARANTSEVAK. A.

аспирант

post-graduate student

sarantsevaka@gmail.comЧЕРНЕНКОП. А.CHERNENKOP. A.

к. м.н., н. с.

MD, PhD, associate scientist

lace@mail.ruАРЗУМАНЯНА. Л.ARZUMANYANA. L.

к. м.н., с. н. с.

MD, PhD, senior staff scientist

Федеральное государственное бюджетное учреждение «Российский онкологический научный центр имени Н. Н. Блохина» Министерства здравоохранения Российской ФедерацииРоссияFGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian FederationRussian Federation201704072017014246Copyright © ЮДИН Д.И., ЛАКТИОНОВ К.П., САРАНЦЕВА К.А., ЧЕРНЕНКО П.А., АРЗУМАНЯН А.Л., 20172017ЮДИН Д.И., ЛАКТИОНОВ К.П., САРАНЦЕВА К.А., ЧЕРНЕНКО П.А., АРЗУМАНЯН А.Л.YUDIN D.I., LAKTIONOV K.P., SARANTSEVA K.A., CHERNENKO P.A., ARZUMANYAN A.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/326

Иммунотерапия активирует иммунную систему пациента с развитием противоопухолевого иммунного ответа. В настоящее время иммуноонкологические препараты широко и успешно применяются для лечения различных видов опухолей. Критерии эффективности, применяемые при оценке химиотерапевтических препаратов, могут привести к значительным сложностям и ошибкам интерпретации ответа на иммунотерапию. Учитывая это, очень важно выбрать соответствующие критерии оценки. Целью этого обзора является освещение этой темы.

Immunotherapies enhance patients’ endogenous immune system function of attacking tumor cells, and are being widely and successfully used in the field of immuno-oncology. Adoption of assumptions based on more traditional chemotherapy-based responses can lead to significant operational difficulties and inaccurate interpretation of responses seen. It is therefore important to choose the appropriate clinical response criteria. These topics are addressed in this white paper.

иммунотерапиясистемы критериев оценки ответа солидных опухолейRECISTIrRCIrRECISTimmunotherapysystem of response evaluation criteria in solid tumorsRECISTIrRCIrRECISTReferencesMiller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207–14.Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207–14.Therasse P., Arbuck S. G. et al.: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000 92(3):205–216.Therasse P., Arbuck S. G. et al.: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000 92(3):205–216.Eisenhauer E. A., Therasse P., Bogaerts J. et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). In: Eur. J. Cancer. 45, Nr. 2, Januar 2009, S. 228–47.Eisenhauer E. A., Therasse P., Bogaerts J. et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). In: Eur. J. Cancer. 45, Nr. 2, Januar 2009, S. 228–47.Laktionov K. K., Sarantseva K. A., Breder V. V. et al. Immunotherapy for non-small cell lung cancer treatment. Malignant Tumours 2016; 3: 18–26.Laktionov K. K., Sarantseva K. A., Breder V. V. et al. Immunotherapy for non-small cell lung cancer treatment. Malignant Tumours 2016; 3: 18–26.Park J., Kwon M., Shin E. C. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016 Nov; 39(11):1577–1587.Park J., Kwon M., Shin E. C. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016 Nov; 39(11):1577–1587.Sarantseva K. A., Laktionava L. V., Reutova E. V., Chernenko P. A., Breder V. V. Immunology: immune response as leading protectionfactor against cancer. Malignant Tumours 2016; 2: 5–14.Sarantseva K. A., Laktionava L. V., Reutova E. V., Chernenko P. A., Breder V. V. Immunology: immune response as leading protectionfactor against cancer. Malignant Tumours 2016; 2: 5–14.Chiou V. L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1; 33(31):3541–3.Chiou V. L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1; 33(31):3541–3.Wolchok J. D., Hoos A., Bohnsack O. et.al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clin Cancer Res 2009; 15(23) December 1, 2009.Wolchok J. D., Hoos A., Bohnsack O. et.al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clin Cancer Res 2009; 15(23) December 1, 2009.Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936–43.Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936–43.Nishino M., Gargano M., Suda M., Ramaiya N. H., Hodi F. S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2: 17. doi:10.1186/2051–1426–2–17.Nishino M., Gargano M., Suda M., Ramaiya N. H., Hodi F. S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2: 17. doi:10.1186/2051–1426–2–17.Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, et al. Immune-related response assessment during PD‑1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4: 84.Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, et al. Immune-related response assessment during PD‑1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4: 84.

The authors declare that there are no conflicts of interest present.